Navigation Links
Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision

MADISON - For the millions of Americans whose vision is slowly ebbing due to degenerative diseases of the eye, the lowly neural progenitor// cell may be riding to the rescue.

In a study in rats, neural progenitor cells derived from human fetal stem cells have been shown to protect the vision of animals with degenerative eye disease similar to the kinds of diseases that afflict humans. The new study appears today (March 28) in the journal Public Library of Science (PLoS) One.

The lead author of the study, University of Wisconsin-Madison researcher David Gamm, says the cells - formative brain cells that arise in early development - show 'some of the best rescue, functionally and anatomically' of any such work to date. In animals whose vision would typically be lost to degenerative retinal disease, the cells were shown to protect vision and the cells in the eye that underpin sight.

The new findings are important because they suggest there may be novel ways to preserve vision in the context of degenerative diseases for which there are now no effective treatments. Macular degeneration, an age-related affliction that gradually destroys central vision, is a scourge of old age, robbing people of the ability to read, recognize faces and live independently.

The finding that the brain cells protected the cells in the eye was a surprise, according to Raymond D. Lund, an author of the new study and an eye disease expert at the University of Utah and the Oregon Health and Sciences University. The neural progenitor cells, which arise from stem cells and further differentiate into different types of cells found in the central nervous system, were being tested for their ability to deliver another agent, a growth factor that has been shown to be effective in treating some types of degenerative disease.

What was surprising, say Gamm and Lund, was that the cells alone demonstrated a remarkable ability to rescue vision.

'On their own, they were able to support retinal cells and keep them alive,' says Lund, who has conducted pioneering studies of cell therapy for eye disease. 'We didn't expect that at all. We've used a number of different cell types from different sources and these have given us the best results we've ever got.'

How the cells act to preserve the deteriorating eye cells remains unknown, says Gamm. Like all cells, neural progenitor cells do many things and secrete many different types of chemicals that may influence the cells around them.

'The idea was to test the cells as a continuous delivery system' to shuttle an agent known as glial cell line-derived neurotrophic factor or GDNF, Lund explains. 'It's not a sensible thing to inject the eyes many times over years. The idea was to use the cells as a continuous delivery system, but we found they work quite well on their own.'

Lund has experimented with other cell types as therapies for preserving vision. The neural progenitor cells, a cell model developed by Wisconsin stem cell researcher Clive Svendsen, have been used experimentally to deliver the same growth factor in models of Parkinson's disease and Lou Gehrig's disease. Svendsen is also an author of the new PloS One report.

'It seems that the cells in and of themselves are quite neuroprotective,' says Gamm. 'They don't become retinal cells. They maintain their own identity, but they migrate within the outer and inner retina' where they seem to confer some protection to the light-sensing cells that typically die in the course of degenerative eye disease.

For researchers, the work is intriguing because the progenitor cells come from the brain itself, and not from the part of the nervous system devoted to vision.

'This cell type isn't derived from the retina. It is derived from the brain,' says Gamm. 'But we're not asking it to become a retina. They survive in the environment of the eye an d don't disrupt the local architecture. They seem to live in a symbiotic relation ship' with retinal cells.

Gamm and Lund emphasize that the new work is preliminary, and that much remains to be done before the cells can be tested in humans: 'The first thing is to show that something works, which we have done,' says Lund. 'Now we need to find out why, but this is a good jumping off point.'

Source-Eurekalert
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... it has been awarded the prestigious Distinguished Emerald Club of the World award, ... by BoardRoom magazine, one of the most respected trade publications serving private clubs. ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... based company that has evolved from humble beginnings to being an internationally recognized leader ... company that we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized ...
(Date:2/10/2016)... FLA (PRWEB) , ... February 09, 2016 , ... ... team at Clevens Face and Body Specialists are delighted to welcome a new ... ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... REDWOOD CITY, Calif. , Feb. 9, 2016 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it will release financial results for the fourth quarter ... Monday, February 29, 2016. Company management will host a ... p.m. Eastern Time) on Monday, February 29, 2016. ...
(Date:2/9/2016)... Feb. 9, 2016  Insulet Corporation (NASDAQ: PODD ) ... pump technology with its OmniPod ® ... has been appointed to Insulet,s Board of Directors. With ... eight of whom are independent. --> ... audit and finance experience and a deep knowledge of accounting, ...
(Date:2/9/2016)... 9, 2016 QGEN ... den Abschluss eines Kooperationsvertrags mit 10x Genomics ... in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology und ... Frankfurt Prime Standard: QIA) gab heute den ... die Entwicklung und Förderung umfassender Lösungen in ...
Breaking Medicine Technology: